Critical Contrast: Oxford Immunotec Global PLC (OXFD) vs. Sequenom (SQNM)
Sequenom (NASDAQ: SQNM) and Oxford Immunotec Global PLC (NASDAQ:OXFD) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, earnings, risk, valuation and dividends.
This is a summary of current recommendations and price targets for Sequenom and Oxford Immunotec Global PLC, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Oxford Immunotec Global PLC||0||0||3||0||3.00|
Oxford Immunotec Global PLC has a consensus target price of $22.00, suggesting a potential upside of 30.95%. Given Oxford Immunotec Global PLC’s higher probable upside, analysts plainly believe Oxford Immunotec Global PLC is more favorable than Sequenom.
Risk and Volatility
Sequenom has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Oxford Immunotec Global PLC has a beta of -0.08, meaning that its stock price is 108% less volatile than the S&P 500.
Earnings and Valuation
This table compares Sequenom and Oxford Immunotec Global PLC’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Oxford Immunotec Global PLC||$97.44 million||4.40||-$23.66 million||($1.50)||-11.20|
Sequenom has higher revenue, but lower earnings than Oxford Immunotec Global PLC. Oxford Immunotec Global PLC is trading at a lower price-to-earnings ratio than Sequenom, indicating that it is currently the more affordable of the two stocks.
This table compares Sequenom and Oxford Immunotec Global PLC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Oxford Immunotec Global PLC||-34.58%||-35.76%||-21.67%|
Institutional & Insider Ownership
46.0% of Sequenom shares are owned by institutional investors. Comparatively, 79.2% of Oxford Immunotec Global PLC shares are owned by institutional investors. 3.1% of Sequenom shares are owned by company insiders. Comparatively, 8.1% of Oxford Immunotec Global PLC shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Oxford Immunotec Global PLC beats Sequenom on 6 of the 10 factors compared between the two stocks.
Sequenom Company Profile
Sequenom, Inc. is a life sciences company. The Company serves patients and physicians by providing early patient management information. The Company operates through Sequenom Laboratories segment. It conducts its business as a molecular diagnostics clinical laboratory located in San Diego, California and Raleigh-Durham, North Carolina. Its testing focus is on prenatal health that includes molecular-based laboratory developed tests (LDTs). The Company’s diagnostic services are provided through its subsidiary, Sequenom Center for Molecular Medicine LLC (SCMM), doing business as Sequenom Laboratories. Sequenom Laboratories develops and validates its tests to be used as a testing service to physicians. Sequenom Laboratories is focused on developing and offering a menu of tests for prenatal continuum of care. The Sequenom Laboratories’ test offerings in the prenatal market include MaterniT21 PLUS LDT, HerediT CF test, SensiGene RhD test, VisibiliT test and Test Send-out Agreements.
Oxford Immunotec Global PLC Company Profile
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. Its T-SPOT.TB test is used to test for tuberculosis (TB), infection and leverages its T-SPOT technology platform, which allows it to measure the response of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease. Its T-SPOT. CMV and T-SPOT. PRT tests are part of its product line focused on the transplantation market.
Receive News & Ratings for Sequenom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sequenom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.